HK1041263A1 - 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders - Google Patents
3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disordersInfo
- Publication number
- HK1041263A1 HK1041263A1 HK02102941.4A HK02102941A HK1041263A1 HK 1041263 A1 HK1041263 A1 HK 1041263A1 HK 02102941 A HK02102941 A HK 02102941A HK 1041263 A1 HK1041263 A1 HK 1041263A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benz
- indol
- obesity
- tetrahydro
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13266099P | 1999-05-05 | 1999-05-05 | |
| PCT/US2000/010981 WO2000068197A1 (en) | 1999-05-05 | 2000-04-20 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1041263A1 true HK1041263A1 (en) | 2002-07-05 |
Family
ID=22455028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK02102941.4A HK1041263A1 (en) | 1999-05-05 | 2002-04-18 | 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1177172A1 (en) |
| AU (1) | AU4659200A (en) |
| CA (1) | CA2373035A1 (en) |
| HK (1) | HK1041263A1 (en) |
| MX (1) | MXPA01011321A (en) |
| WO (1) | WO2000068197A1 (en) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396809B1 (en) | 1999-02-10 | 2008-07-08 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| US7745216B2 (en) | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| US6989379B1 (en) | 1999-04-22 | 2006-01-24 | H. Lundbick A/S | Selective NPY (Y5) antagonists |
| EP1816127A1 (en) * | 1999-04-22 | 2007-08-08 | H. Lundbeck A/S | Triazine derivatives for use as selective npy (y5) antagonists |
| US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
| US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
| EP1249233B9 (en) | 1999-11-26 | 2009-08-05 | Shionogi & Co., Ltd. | Npyy5 antagonists |
| BR0116206A (en) * | 2000-12-14 | 2003-12-23 | Amylin Pharmaceuticals Inc | Yy Peptide and yy Peptide Agonists for Treatment of Metabolic Disorders |
| AU2007200224B2 (en) * | 2000-12-14 | 2009-10-01 | Amylin Pharmaceuticals, Llc | Peptide YY and peptide YY agonists for treatment of metabolic disorders |
| KR100989647B1 (en) | 2001-09-24 | 2010-10-26 | 오레곤 헬스 앤드 사이언스 유니버시티 | Modification of feeding behavior |
| CA2403307A1 (en) | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| BR0306625A (en) * | 2002-05-23 | 2006-04-18 | Abbott Lab | acetamides and benzamides that are helpful in treating sexual dysfunction |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ZA200508439B (en) | 2003-05-05 | 2007-03-28 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
| AU2004274309B2 (en) | 2003-09-22 | 2010-04-08 | Msd K.K. | Novel piperidine derivative |
| US20050137142A1 (en) | 2003-11-03 | 2005-06-23 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| WO2005077094A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Method of treating men with metabolic and anthropometric disorders |
| DK1814590T4 (en) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals Llc | Treatment of obesity and related diseases. |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| EP1892241B1 (en) | 2005-05-30 | 2016-03-30 | Msd K.K. | Novel piperidine derivative |
| JPWO2007018248A1 (en) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | Pyridone compounds |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| EP1921065B1 (en) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| JPWO2007029847A1 (en) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | Bicyclic aromatic substituted pyridone derivatives |
| US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| RU2008119687A (en) | 2005-10-21 | 2009-11-27 | Новартис АГ (CH) | COMBINATIONS OF ORGANIC COMPOUNDS |
| CA2627139A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
| KR101318127B1 (en) | 2005-11-10 | 2013-10-16 | 엠에스디 가부시키가이샤 | Aza-substituted spiro derivative |
| CA2650683A1 (en) | 2006-04-28 | 2007-11-08 | Shionogi & Co., Ltd. | Amine derivative having npy y5 receptor antagonist activity |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| WO2008047544A1 (en) | 2006-09-28 | 2008-04-24 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| JP5379692B2 (en) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases |
| JP5523107B2 (en) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | Novel inhibitors of glutaminyl cyclase |
| TWI428346B (en) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JP5930573B2 (en) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | New use of glutaminyl cyclase inhibitors |
| JP5319518B2 (en) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | Indoledione derivative |
| ES2533484T3 (en) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| SA08290668B1 (en) | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
| EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | Alkylaminopyridine derivative |
| AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| CA2930674A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2009154132A1 (en) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Spirodiamine-diarylketoxime derivative |
| EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102272103B (en) | 2008-10-30 | 2015-10-21 | 默沙东公司 | Isonicotinamide orexin receptor antagonists |
| JP5557845B2 (en) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
| EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US8227618B2 (en) | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
| DK2475428T3 (en) | 2009-09-11 | 2015-09-28 | Probiodrug Ag | Heterocyclic derivatives as glutaminylcyklaseinhibitorer |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| BR112012022478B1 (en) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | HETEROCYCLIC GLUTAMINYL CYCLASE INHIBITORS (QC, EC 2.3.2.5), THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| JP5728099B2 (en) | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents |
| DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| AR088352A1 (en) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (en) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC BICYCLIC COMPOUNDS |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2021109549A (en) | 2014-08-29 | 2021-05-13 | Тес Фарма С.Р.Л. | Α-AMINO-β-CARBOXYMUCONATE INHIBITORS of ε-SEMIALDEHYDE-DECARBOXYLASE |
| AR109950A1 (en) | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | A-AMINO-b-CARBOXIMUCONIC SEMIAL DEHYDE DECARBOXYLASE ACID INHIBITORS |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| DK3461819T3 (en) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | GLUTAMINYL CYCLASE INHIBITORS |
| AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
| EP3924058A1 (en) | 2019-02-13 | 2021-12-22 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| IL300610A (en) | 2020-08-18 | 2023-04-01 | Merck Sharp ַ& Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7692996A (en) * | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| WO1997019682A1 (en) * | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| JP2000510164A (en) * | 1997-02-14 | 2000-08-08 | バイエル・コーポレーシヨン | Amide derivatives as selective neuropeptide Y receptor antagonists |
| TR200100137T2 (en) * | 1998-04-29 | 2001-05-21 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. |
| ES2235521T3 (en) * | 1998-10-07 | 2005-07-01 | Ortho-Mcneil Pharmaceutical, Inc. | N-ARALQUILAMINOTETRALINA AS BINDING FOR THE NEUROPEPTIDE AND RECEIVER Y5. |
-
2000
- 2000-04-20 MX MXPA01011321A patent/MXPA01011321A/en unknown
- 2000-04-20 CA CA002373035A patent/CA2373035A1/en not_active Abandoned
- 2000-04-20 EP EP00928340A patent/EP1177172A1/en not_active Withdrawn
- 2000-04-20 WO PCT/US2000/010981 patent/WO2000068197A1/en not_active Application Discontinuation
- 2000-04-20 AU AU46592/00A patent/AU4659200A/en not_active Abandoned
-
2002
- 2002-04-18 HK HK02102941.4A patent/HK1041263A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000068197A1 (en) | 2000-11-16 |
| CA2373035A1 (en) | 2000-11-16 |
| AU4659200A (en) | 2000-11-21 |
| MXPA01011321A (en) | 2003-08-01 |
| EP1177172A1 (en) | 2002-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1041263A1 (en) | 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders | |
| MXPA02000927A (en) | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders. | |
| HUP0102656A3 (en) | N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders and medicaments containing them | |
| IL147582A0 (en) | 2-arylimino-2, 3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands | |
| HUP0104816A3 (en) | 3-azabicyclo[3.1.0] hexane derivatives as opiate receptors ligands and process for their preparation | |
| HUP0402113A3 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof | |
| AU2003291609A1 (en) | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | |
| GB2367060B (en) | Alzheimer's disease secretase,app substrates therefor,and uses therefor | |
| HK1070361A1 (en) | 5-sulphanyl-4h-1,2,4-triazole derivatives and their use to treat disorders associated with somatostatine | |
| IL148419A0 (en) | Benzodiazepine derivatives, the production and use thereof | |
| HK1056877A1 (en) | Mch antagonists and their use in the treatment of obesity. | |
| IL154272A0 (en) | The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | |
| GB9911053D0 (en) | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents | |
| EP1233785A4 (en) | "bonzo" chemokine receptor antibodies and ligands | |
| IL151426A0 (en) | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | |
| IL150022A0 (en) | Imidazo [1,3,5] triazinones and the use thereof | |
| EP1174484A4 (en) | Water-and-oil repellant composition and process for producing the same | |
| IL156340A0 (en) | 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders | |
| NZ513680A (en) | Epitodes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses | |
| HK1041226A1 (en) | Methods and compositions for treating gastro-esophageal reflux disease | |
| GB2370233B (en) | Apparatus for use in behaviour modification and the like | |
| AU8177801A (en) | 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists | |
| AU3958902A (en) | Crf receptor antagonists and methods relating thereto | |
| IL136296A0 (en) | Catalyst, process for its preparation, and its use in the synthesis of 1,2-dichloroethane | |
| GB2364303B (en) | Semiconducting ceramic material and electronic part employing the same |